ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention.

Published

Journal Article

Currently, we lack biomarkers to predict whether high-risk women with mammary atypia will respond to tamoxifen chemoprevention.Thirty-four women with cytologic mammary atypia from the Duke University High-Risk clinic were offered tamoxifen chemoprevention. We tested whether ESR1 promoter hypermethylation and/or estrogen receptor (ER) protein expression by immunohistochemistry predicted persistent atypia in 18 women who were treated with tamoxifen for 12 months and in 16 untreated controls.We observed a statistically significant decrease in the Masood score of women on tamoxifen chemoprevention for 12 months compared with control women. This was a significant interaction effect of time (0, 6, and 12 months) and treatment group (tamoxifen versus control) P = 0.0007. However, neither ESR1 promoter hypermethylation nor low ER expression predicted persistent atypia in Random Periareolar Fine Needle Aspiration after 12 months tamoxifen prevention.Results from this single institution pilot study provide evidence that, unlike for invasive breast cancer, ESR1 promoter hypermethylation and/or low ER expression is not a reliable marker of tamoxifen-resistant atypia.

Full Text

Duke Authors

Cited Authors

  • Baker, JC; Ostrander, JH; Lem, S; Broadwater, G; Bean, GR; D'Amato, NC; Goldenberg, VK; Rowell, C; Ibarra-Drendall, C; Grant, T; Pilie, PG; Vasilatos, SN; Troch, MM; Scott, V; Wilke, LG; Paisie, C; Rabiner, SM; Torres-Hernandez, A; Zalles, CM; Seewaldt, VL

Published Date

  • August 2008

Published In

Volume / Issue

  • 17 / 8

Start / End Page

  • 1884 - 1890

PubMed ID

  • 18708376

Pubmed Central ID

  • 18708376

Electronic International Standard Serial Number (EISSN)

  • 1538-7755

International Standard Serial Number (ISSN)

  • 1055-9965

Digital Object Identifier (DOI)

  • 10.1158/1055-9965.EPI-07-2696

Language

  • eng